OAM
CBPO

Oppenheimer Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Oppenheimer Asset Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,512
Closed -$171K – 1751
2017
Q2 		$171K Sell
1,512
-43
-3% -$4.8K ﹤0.01% 1072
2017
Q1 		$156K Buy
+1,555
New +$166K ﹤0.01% 1097

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return

Oppenheimer Asset Management's CBPO Position: Q3 2017 in Review

Oppenheimer Asset Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2017, closing a stake of 1,512 shares — an estimated $171K sold.

Oppenheimer Asset Management first reported a position in CBPO in Q1 2017 and held it in 2 quarters. The position peaked at $171K in Q2 2017. 94 funds tracked by Wall St. Rank hold CBPO as of Q3 2017.

  • Oppenheimer Asset Management reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2017 after selling out during the quarter.
  • Oppenheimer Asset Management sold 1,512 China Biologic Products Holdings, Inc. shares in Q3 2017, an estimated $171K.
  • Oppenheimer Asset Management first reported a position in China Biologic Products Holdings, Inc. in Q1 2017 and held it in 2 quarters.
  • Oppenheimer Asset Management's China Biologic Products Holdings, Inc. position peaked at $171K in Q2 2017.
  • 94 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2017.

Based on Oppenheimer Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.